EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 12 (Décembre 2023) Med Sci (Paris), 39 12 (2023) 958-966 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 12, Décembre 2023
Page(s) 958 - 966
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023177
Publié en ligne 18 décembre 2023
  1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014 ; 2 : e106–e116. [CrossRef] [PubMed] [Google Scholar]
  2. Garcia-Garcia J, Usategui-Martin R, Sanabria MR, et al. Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment. Ophthalmic Res 2022; 65 : 615–36. [CrossRef] [PubMed] [Google Scholar]
  3. Spooner K, Mhlanga C, Hong T, et al. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol 2018 ; 12 : 2483–2491. [CrossRef] [Google Scholar]
  4. Fonteh CN, Mathias MT, Mandava N, et al. Mental health and visual acuity in patients with age-related macular degeneration. BMC Ophthalmol 2022; 22 : 391. [CrossRef] [PubMed] [Google Scholar]
  5. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006 ; 58 : 353–363. [PubMed] [Google Scholar]
  6. Roubeix C, Sahel JA, Guillonneau X, et al. Sur les origines inflammatoires de la DMLA. Med Sci (Paris) 2020; 36 : 886–92. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol 2001 ; 119 : 1417–1436. [CrossRef] [PubMed] [Google Scholar]
  8. Davis MD, Gangnon RE, Lee L-Y, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005 ; 123 : 1484–1498. [CrossRef] [PubMed] [Google Scholar]
  9. Bakri SJ, Bektas M, Sharp D, et al. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm 2023; 29 : S2–S11. [PubMed] [Google Scholar]
  10. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 2023; 402 : 1449–58. [CrossRef] [PubMed] [Google Scholar]
  11. Leveziel N, Soubrane G, Souied EH. Anti-VEGF : applications pratiques en ophtalmologie. Med Sci (Paris) 2009 ; 25 : 1105–1107. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Schultz NM, Bhardwaj S, Barclay C, et al. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther 2021; 43 : 1792–818. [CrossRef] [PubMed] [Google Scholar]
  13. Doshi RR, Bakri SJ, Fung AE. Intravitreal Injection Technique. Semin Ophthalmol 2011 ; 26 : 104–113. [CrossRef] [PubMed] [Google Scholar]
  14. Pina Marín B, Gajate Paniagua NM, Gómez-Baldó L, et al. Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study. Eur J Ophthalmol 2022; 32 : 385–94. [CrossRef] [PubMed] [Google Scholar]
  15. Hollaus M, Bühl W, Schmidt-Erfurth U, et al. The Challenges of Treating Neovascular Age-Related Macular Degeneration. Klin Monbl Augenheilkd 2022; 239 : 1033–42. [CrossRef] [PubMed] [Google Scholar]
  16. Korobelnik J-F, Delcourt C, Creuzot-Garcher C, et al. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. J Med Econom 2021; 24 : 1087–97. [CrossRef] [PubMed] [Google Scholar]
  17. Boyle J, Vukicevic M, Koklanis K, et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychology, Health & Medicine 2018 ; 23 : 127–140. [CrossRef] [PubMed] [Google Scholar]
  18. Li E, Donati S, Lindsley KB, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2020; 5 : CD012208. [PubMed] [Google Scholar]
  19. del Amo EM, Rimpelä A-K, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res 2017 ; 57 : 134–185. [CrossRef] [PubMed] [Google Scholar]
  20. Singh M, Bharadwaj S, Lee KE, et al. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. J Control Release 2020; 328 : 895–916. [CrossRef] [PubMed] [Google Scholar]
  21. Herrera-Barrera M, Ryals RC, Gautam M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv 2023; 9 : eadd4623. [CrossRef] [PubMed] [Google Scholar]
  22. Xu J, Xue Y, Hu G, et al. A comprehensive review on contact lens for ophthalmic drug delivery. J Control Release 2018 ; 281 : 97–118. [CrossRef] [PubMed] [Google Scholar]
  23. National Institutes of Health Clinical Center (CC). A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration. clinicaltrials.gov, 2020. https://clinicaltrials.gov/ct2/show/NCT00306488. [Google Scholar]
  24. Alcon Research. The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2014. https://clinicaltrials.gov/ct2/show/NCT00890097. [Google Scholar]
  25. MacuCLEAR, Inc., Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration. clinicaltrials.gov, 2014. https://clinicaltrials.gov/ct2/show/study/NCT02127463. [Google Scholar]
  26. Vogl W-D, Riedl S, Mai J, et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina 2023; 7 : 4–13. [CrossRef] [PubMed] [Google Scholar]
  27. CoMentis. A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab). clinicaltrials.gov, 2010. https://clinicaltrials.gov/ct2/show/study/NCT00607750. [Google Scholar]
  28. GlaxoSmithKline. MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. clinicaltrials.gov, 2017. https://clinicaltrials.gov/ct2/show/study/NCT01134055. [Google Scholar]
  29. Bayer. A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration. clinicaltrials.gov, 2016. https://clinicaltrials.gov/ct2/show/NCT02222207. [Google Scholar]
  30. Poor SH, Weissgerber G, Adams CM, et al. A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol 2022; 239 : 180–9. [CrossRef] [PubMed] [Google Scholar]
  31. Ohr Pharmaceutical Inc. OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2017. https://clinicaltrials.gov/ct2/show/study/NCT02727881. [Google Scholar]
  32. PanOptica, Inc. A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2019. https://clinicaltrials.gov/ct2/show/NCT03479372. [Google Scholar]
  33. Chaney P. PAN-90806: once-daily topical anti-VEGF eye drop for wet AMD and other neovascular eye disease. Ophthalmology Innovation Summit, San Francisco 2019. https://www.panopticapharma.com/wp-content/uploads/2019/10/PAN-90806-Data-at-OIS@AAO.pdf. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.